

Technology Advisory Committee A Interests Register

Topic: Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer [ID6220]

Publication Date: 15/01/2025

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Becky Pennington	Committee member	Indirect - Financial	Becky has an ongoing project with Eli Lilly relating to carer utilities - not related to pemetrexed or this disease area.	10/09/2024	It was agreed that Becky's declaration would not prevent her from participating in discussions on this appraisal
Michael Chambers	Committee Member	Indirect - Financial	Michael participated in an advisory panel for Pfizer (comparator company), but in an unrelated disease area (prostate cancer)	10/09/2024	It was agreed that Michael's declaration would not prevent him participating in discussions on this appraisal
Dominic Pivonka	Committee Member	Indirect – Financial	Dominic's employer (AbbVie) has treatments being evaluated for non-small-cell lung cancer in phase 1-3 studies. The most advanced is Telisotuzumab vedotin which is in Phase 3. There is the below topic in	10/09/2024	It was agreed that NAME's declaration would not prevent him participating in discussions on this appraisal

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>the work programme, but we are yet to confirm regulatory filing plans.</p> <ul style="list-style-type: none"> • Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253] <p>The other treatments are at an earlier stage.</p> <ul style="list-style-type: none"> • ABBV-151 (livmoniplimab) + ABBV-181 (budigalimab) – Phase 2 • ABBV-400 – Phase 1 • ABBV-514 – Phase 1 		